Clinical Trials Directory

Trials / Completed

CompletedNCT02440178

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

Phase II Trial of Micafungin Prophylaxis During Induction Chemotherapy for Patients With Acute Leukemia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether prophylaxis with micafungin is effective in the induction chemotherapy for newly diagnosed acute leukemia patients.

Detailed description

Medically fit patients with newly diagnosed acute leukemia received 50 mg micafungin intravenously once daily from the initiation of first induction chemotherapy to recovery of neutrophil count, suspected fungal infection, or unacceptable drug-related toxicity.

Conditions

Interventions

TypeNameDescription
DRUGMicafungin

Timeline

Start date
2015-09-19
Primary completion
2017-06-01
Completion
2017-06-01
First posted
2015-05-12
Last updated
2021-11-09
Results posted
2021-11-09

Source: ClinicalTrials.gov record NCT02440178. Inclusion in this directory is not an endorsement.

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia (NCT02440178) · Clinical Trials Directory